• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
+49 (0) 69 / 606 278 – 0
[email protected]
Contact form
Patent- & Rechtsanwaltskanzlei

Patent- & Rechtsanwaltskanzlei

  • Deutsch

+49 (0) 69 / 606 278 – 0

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • xing
  • Email
MENUMENU
  • Services
    • Advice On Protective IP Rights
    • Patent Application /TM Registration
    • Enforcement Of IP Rights
    • Defence Against IP Rights Enforcement
    • Costs
  • Company
    • Fields of Law
      • Patent Law
      • Utility Model Law
      • Employees’ Inventions
      • Trademark Law
      • Design Law
      • Trademark and Product Piracy
      • Expert Opinions
    • Our Law Firm
      • Dr. Karl-Hermann Meyer-Dulheuer
      • Dr. Tim Meyer-Dulheuer
      • Dr. Klaus Zimmermann
      • Zhichao Ying
      • Clara Elinor Grünewald
    • Commitment
  • Contact
    • Where To Find Us
    • Write us!
    • Request call back
  • Blog

New evidence in an inter part review possible – and even to be expected

18. June 2018

Evidence can be introduced during the IPR process – and not only if the patent holder has not yet had an opportunity to respond. The U.S. Federal Court of Appeals upheld the decision of the PTAB against a patent claim for a drug against fungal infections.

Anacor Pharmaceuticals in an Inter Partes Review

nail infectionThe focus of the dispute was Anacor Pharmaceuticals and its claimed patent No. 7,582,621 against nail infections caused by fungal infections (Anacor Pharmaceuticals, Inc. v. Iancu, 2018 WL 2187768). The patent claimed by Anacor related to the use of 1,3-dihydro-5-fluor-1-hydroxy-2, 1-benzoxaborol, also known as tavaborol. This is listed in the Orange Book as KERYDIN® (tavaborol) – a topical antifungal treatment of nail onychomycosis. The controversial’621 patent claims methods for the treatment of infection with tavaborol, another’657 patent claims pharmaceutical formulations of tavaborol.

The US Patent Trial and Appeal Board (PTAB) annulled the’621 patent claims for the combination of the Austin and Brehove patent publications and the combination of Austin and Freeman. Anacor had combined the references Austin and Brehove and argued that an average expert would not have combined the references because they concern structurally different links. However, the Federal Circuit made it clear that Austin revealed that tavaborol is a known fungicide with particular efficacy against C. albicans and that molecular weight is the most important factor in predicting whether a molecule will penetrate the nail plate. There are structural differences between the dioxaborinanes of Brehove and the benzoxaborols of Austin, but their structural similarities and similar fungicidal effects are decisive. Any expert could rightly expect that the functional activity against dermatophytes and also Candida Albicans (the causers of nail infections) would be confirmed in the combination of Austin and Brehove.

The second aspect in this case: the Inter Partes Review

In the appeal, Anacor argued that the Board had violated the due process and procedural requirements of the Administrative Procedure Act (APA) by failing to sufficiently inform Anacor about a new theory of obviousness and new evidence not contained in the petition and to give it an opportunity to comment.

The Federal Court of Justice found that there was expressly no prohibition at all against the introduction of new evidence during an inter part review. Anacor had not been denied its procedural rights since the final written decision was based on the same combination of primary references and the same set of conclusions proposed in the petition.

A petitioner in an Inter Partes Review may submit new evidence not included in his petition if:

1) the evidence is a reply to the evidence provided by the patent proprietor

2) or the evidence documents the knowledge that an average expert would bring to reading the state of the art identified as obvious.

Since 2012 – with the revision of the American Patent Act by the America Invents Act (AIA) – a special procedure called the Inter Partes Review has been available for filing a patent application with the US Patent Office. This makes it possible to challenge a granted patent not only with an elaborate nullity action before a court, but with a considerably less elaborate administrative procedure before the patent office. A special feature of this procedure is that the patent office only opens the procedure if the justification of the application indicates a reasonable likelihood of success. The decision of acceptance of the proceedings by the Patent Office is subject to U. S. Patent Law final and not subject to appeal.

Conclusion:

In some cases, an applicant can benefit from the introduction of new evidence by responding to the argument of non-obviousness of a patent holder. Additional evidence of the prior art at the time of the invention may be useful to disprove arguments of the patent proprietor as to knowledge of the prior art. In any case, the introduction of new evidence in the course of an inter part review is not only permissible, but has even to be expected.

Patent protection – a topic for you too?

Our law firm has many years of expertise, also in the pharmaceutical and chemical sector. Request a non-binding callback today:

 

 

 

Sources:

Anacor Pharmaceuticals, Inc. v. Iancu, 2018 WL 2187768

Picture:

181381 / pixabay.com / CCO License

  • share  
  • share 
  • share 
  • tweet  
  • share 

Category iconHealthcare & Lifesciences,  Patent Law Tag iconPatent,  inter partes review,  patent protection,  PTAB,  U.S.,  Anacor Pharmaceuticials,  U. S. Board of Appeals,  new evidence,  Anacor

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

More articles about: Healthcare & Lifesciences

All articles

Blog Menu

  • Design Law
  • Healthcare & Lifesciences
  • International Intellectual Property
  • Licenses
  • News from our law firm
  • Overall
  • Patent Law
  • Product- and Trademark piracy
  • Trademark Law
This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form

Recent Posts

  • Action against a patent already expired 26. February 2021
  • Design protection in China: Amendment 2021 25. February 2021
  • EPO practice of national patent offices – more uniform 18. February 2021
  • BGH: Black Forest ham – not only packaged in the Black Forest 16. February 2021

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Das könnte Sie auch interessieren:

26. February 2021
Action against a patent already expired

Action against a patent already expired

18. February 2021
EPO practice of national patent offices – more uniform

EPO practice of national patent offices – more uniform

15. February 2021
Employee’s invention in insolvency

Employee’s invention in insolvency

12. February 2021
Equivalence ruling of BGH: ‘Equivalent means’ in case Crane arm

Equivalence ruling of BGH: ‘Equivalent means’ in case Crane arm

5. February 2021
Trade secret: what are ‘appropriate’ secrecy measures?

Trade secret: what are ‘appropriate’ secrecy measures?

29. January 2021
Brexit: Changes for UK patent attorneys in GER

Brexit: Changes for UK patent attorneys in GER

Footer

Contact

Franklinstr. 61-63
D-60486 Frankfurt am Main
Germany

+49 (0) 69 / 606 278 – 0
+49 (0) 69 / 606 278 – 199
[email protected]

Customer Reviews

Meyer-Dulheuer MD Legal Patentanwälte PartG mbB Patentrecht, Markenrecht, Eigentum hat 4,78 von 5 Sternen 23 Bewertungen auf ProvenExpert.com

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Law Firm

  • Request non-binding call back
  • Info secure emails
  • Company
  • Our Law Firm
  • ISO Certificate
  • Privacy Policy
  • Data handling for clients
  • Imprint

Follow Us

  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • xing
  • Email

Newsletter Signup

This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form

© Patent- & Rechtsanwaltskanzlei Meyer-Dulheuer MD Legal Patentanwälte PartG mbB

Kontaktformular

 

Rufen Sie uns an, schicken Sie uns eine Mail oder füllen Sie das Kontaktformular aus.

+49 (0) 69 / 606 278 – 0
[email protected]

This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form

Contact Form

 

Give us a call, send us an email or fill out the contact form.

+49 (0) 69 / 606 278 – 0
[email protected]

This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form